ACADIA Pharmaceuticals Inc. (ACAD) analyst actions
Rating and price-target actions on ACAD in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ACAD overview →
3 measured ACAD analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ACADIA Pharmaceuticals Inc. (ACAD) And Encourages Stockholders to Reach Out | Press release | +0.03% | -0.18% | |
| Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome | Press release | -0.71% | -0.54% | |
| Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis | Press release | -1.40% | -0.32% |
Keep exploring
More ACAD: earnings → · SEC filings → · ACAD overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kazia Therapeutics Limited - American Depositary Shares (KZIA) | 393 | -1.07% | 34% |
| OHR PHARMACEUTICALS (OHRP) | 393 | 0.00% | 48% |
| BioXcel Therapeutics, Inc. (BTAI) | 392 | -0.75% | 41% |
| Karyopharm Therapeutics Inc. (KPTI) | 392 | -0.45% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.